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Abstract
Antimicrobial stewardship is recog-
nized as a key component to stop the current
European spread of antimicrobial resist-
ance. It has also become evident that
antimicrobial resistance is a problem that
cannot be tackled by single institutions or
physicians. Prevention of antimicrobial
resistance needs rigorous actions at ward
level, institution level, national level and at
supra-national levels. Countries can learn
from each other and possibly transplant best
practices across borders to prevent antimi-
crobial resistance. The aim of this study is
to highlight some of the success stories of
proven cost-effective interventions, and to
describe the actions that have been taken,
the outcomes that have been found, and the
difficulties that have been met. In some
cases we came across substantial scope for
real-life cost savings. Although the best
approach to effectively hinder the spread of
antimicrobial resistance remains unclear
and may vary significantly among settings,
several EU-wide examples demonstrate that
cost-effective antimicrobial stewardship is
possible. Such examples can encourage oth-
ers to implement (the most cost-effective)
elements in their system.
Introduction
Antimicrobial resistance is a worldwide
and growing public healthcare problem.1-3
The recently published Antimicrobial
Resistance: Tackling a Crisis for the Health
and Wealth of Nations shows that increasing
antimicrobial resistance leads to substantial
clinical burden in terms of morbidity, mor-
tality, and lower quality of life.4 Today,
resistant bacteria cause in Europe and the
US only 50,000 deaths per year. However, if
adequate use of antibiotics will not
improve, it has been estimated that in the
year 2050 approximately 10 million people
will die as a consequence of antimicrobial
resistance. The economic burden will also
be substantial, in particular due to addition-
al hospitalizations, expensive secondary
treatment options, and productivity losses at
the labor market. Yet, despite the severe
consequences of inappropriate antibiotic
use and the alarming future projections,
antibiotic use has for example increased
with 4-5% last year in Dutch hospital care.5
A more intense focus on appropriate use of
antibiotics is necessary to keep healthcare
systems sustainable.6
The World Health Organization defines
appropriate use of antibiotics as the cost-
effective use of antibiotics which maximizes
clinical therapeutic effect while minimizing
both drug-related toxicity and the develop-
ment of antimicrobial resistance.6 The
objective of antimicrobial resistance poli-
cies is to ensure patient safety and to keep
future bacterial infections treatable.
Antimicrobial resistance policies addresses
two main mechanisms. First, preventing the
spread of (resistant) micro-organisms by
effective infection control. Second, reduc-
ing inadequate prescription and inadequate
use of antibiotics. To achieve maximum
benefit, these antimicrobial policies should
be implemented in curative care (primary
care and hospital care), and also in long-
term care (nursing and residential homes). 
Several regulators and institutions at the
forefront have shown to limit the spread of
antimicrobial resistance effectively by inter-
ventions such as antimicrobial stewardship
teams, public health campaigns, govern-
mental regulations, improved diagnostics,
and interventions to improve adherence to
infection prevention guidelines. Moreover,
some of them also claimed substantial cost-
effectiveness of their antimicrobial policy
as well as absolute cost savings. Effective
EU-wide implementation and sustained use
of cost-effective antimicrobial policies can
consequently lead to improved safety and
quality of care while contributing to more
sustainable healthcare.
The objective of this article is to pro-
vide examples of infection prevention and
adequate use of antibiotics that have proven
to be both clinically effective and of eco-
nomic value. We describe the content of
these examples and provide insight into the
cost-effectiveness.
Materials and Methods 
We searched for proven cost-effective
examples of Dutch antimicrobial policies
and infection control policies. After select-
ing Dutch examples, an inventory was made
of additional promising EU-wide examples.
First, we created a long-lost of promising
cases based on expert opinion and the per-
sonal networks of the organization commit-
tee of the EU Antimicrobial Resistance One
Health Ministerial Conference (February
2016, Amsterdam, the Netherlands) and the
research team members. From this long-lost
only cases with proven cost-effectiveness
were selected for the shortlist. The final
selection of all examples was also based on
the quality of examples and the type of
antimicrobial policy (to describe a wide
spread of cost-effective policies, imple-
mented across healthcare settings). Thus,
this sample – if broadly implemented –
holds the promise for substantial improve-
ment across entire health systems. The EU-
wide examples were primarily selected to
create a magazine as input for the EU
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Antimicrobial Resistance One Health
Ministerial Conference. The cases in the
current research article are drawn from the
magazine. If the EU-wide institutions were
willing to participate (all were), an invento-
ry was made of the following topics: i) the
content of the antimicrobial policy; ii) the
costs of the antimicrobial policy; and iii) the
effectiveness of the antimicrobial policy. If
available, we used peer-reviewed literature
for the data inventory (high quality evi-
dence). If not available, we used non-peer-
reviewed literature, such as research
reports, conference presentations, or per-
sonal communication with study authors
(lower quality evidence).
Results
In this section, we describe proven cost-
effective examples of a sample of interven-
tions that are directed at reduction of infec-
tions with microorganisms, more adequate
use of antibiotics, a reduction of antimicro-
bial resistance rates, or a combination of
these. We have described both examples of
horizontal approaches at national or hospi-
tal level and vertical approaches (more nar-
row-based programs) at the level of an indi-
vidual hospital ward or primary care prac-
tice.  
Horizontal approaches at hospital
level
Antimicrobial stewardship teams: 
lower- and high-quality evidence 
To control the spread of antimicrobial
resistance, antimicrobial stewardship teams
are mandatory for every Dutch hospital.
Antimicrobial stewardship teams have the
purpose to stimulate adequate antibiotic
use, which should result in a reduction of
antimicrobial resistance rates, less use of
last resort antibiotics, and shorter length of
hospital stay. Stewardship teams will there-
fore enhance quality of care, while also
yielding (large) cost-savings.7
Two Dutch hospitals proved cost-effec-
tiveness of their antimicrobial stewardship
team. The Canisius-Wilhelmina Hospital in
Nijmegen estimated a €40,000 hospital-
wide cost-saving over a 12-month period
after introduction of the antimicrobial stew-
ardship team.8 The team consists of an
internist-infectivologist, a microbiologist, a
pharmacist, and an IT specialist. Key ele-
ments of the Canisius-Wilhelmina Hospital
stewardship team are antimicrobial vigi-
lance alerts (daily monitoring of used
antibiotics), audit-feedback, and a IV-oral
switch program. Implementation of the
antimicrobial stewardship team resulted in
25% less prescription of last resort antibi-
otics, modification of more than half of all
antibiotic prescriptions, and a 1-day earlier
IV-oral switch. 
The University Medical Centre
Groningen (UMCG, the Netherlands) also
proved substantial cost-effectiveness of
their antimicrobial stewardship program. In
addition to the standard routines, the
UMCG program holds an important and
unique element: the face-to-face day 2 case
audit. The aim of this audit is to streamline
therapy as early as possible. The hospital
pharmacist sends an automatic e-mail alert
to all stewardship members 48 hours after
start of antibiotic therapy. This then triggers
a case audit: a stewardship member visits
the ward to discuss the patient’s therapy
with the bedside physician. Together, they
decide on further treatment (e.g., IV-oral
switch and dosage), based on diagnostics
and local guidelines. The applicability of
this therapy will be discussed again after
thirty days of treatment. These face-to-face
consultations are used to create an effective
learning moment. 
The clinical effectiveness and cost-
effectiveness of this antimicrobial steward-
ship team were studied at a urology ward.9,10
Hospital costs from patients in this effec-
tiveness study were compared with a histor-
ical cohort from the same ward: there was a
statistically and clinically significant reduc-
tion in the number of antibiotic prescrip-
tions (Figure 1). In addition, patients
switched significantly earlier from IV to
oral therapy, had a shorter length of hospital
stay, and required less nursing time on the
ICU. During the programs’ first year, the
study group spent almost €70,000 less than
the historical cohort, while the total costs
for the intervention were about €27,000 in
this period. One-off costs for setting up the
program (stewardship meetings and the
development of the pharmacy e-alert pro-
gram) were €17,000. Structural cost for run-
ning this program (case audits, stewardship
meetings, and maintenance of the pharmacy
e-alert program) totaled about €10,000.
This economic evaluation not only strongly
indicates cost-effectiveness of the antimi-
crobial stewardship (a possible return on
investment of 700%), it also shows that a
financial break-even point can be reached
within a few months. It should however be
emphasized that these results only hold for
patients without severe underlying comor-
bidity. Nevertheless, given that both lower
antibiotic use and lower length of stay pre-
dict increasing quality of care, this steward-
ship team seems to have a major impact and
may lead to positive investment returns,
even shortly after implementation (Figure
2). Antimicrobial stewardship is also highly
relevant in long-term care. Given the large
variation in prevalence of resistant bacteria
in long-term care institutions, it is relevant
to monitor prevalence of resistant bacteria
closely.11 Sweden has developed a nation-
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Figure 1. Antibiotic use on a urology department before and after implementation of the
antimicrobial stewardship team.
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wide web-based tool for data collection and
feedback on bacterial infections and antibi-
otic consumption in long-term care.12 Web-
based reporting makes it easy for staff to
register the infections, the prescribed antibi-
otics and the risk factors. It also makes it
possible to evaluate prescribing of antibi-
otics in relation to various infection symp-
toms and how the presence of certain risk
factors relate to the prevalence of infec-
tions. Since data can be easily extracted
from the reporting module, all participating
facilities can get instant feedback on their
own results. Evidence on (cost-)effective-
ness of this web-based tool in long-term
care is not yet available, but given the major
impact of infections on patient safety in
long-term care, this seems a promising way
to approach this problem.
Horizontal approaches at national
level
Public health campaigns – lower- and
high-quality evidence 
Public health campaigns can raise
awareness on responsible antibiotic use. In
France, for example the overall antibiotic
consumption fell by 10.7% (as compared to
a pre-intervention period) during a nation-
wide mass media campaign that lasted from
2002 until 2010 – called microorganisms in
question.13 The campaign used a range of
tools, including TV and radio spots, infor-
mation booklets, and leaflets. Examples of
common slogans used were antibiotics are
not automatic, an antibiotic cannot heal,
and antibiotics, if you use them incorrectly,
they will be less strong. It should however
be highlighted that the observed decrease
might have been caused by other initiatives
in France or elsewhere or by the introduc-
tion of a S. pneumonia vaccine during the
study period. 
Poland celebrates an Antibiotic
Awareness Day each year on the 18th of
November to raise awareness for the threat
posed by antimicrobial resistance, as well as
the need for appropriate use of antibiotics.14
Different stakeholders are engaged: scien-
tific societies, outpatient clinics, hospitals,
schools, government bodies, public trans-
port, television, radio, the press. Some
information about antimicrobial resistance
and the use of antibiotics are disseminated
in the form of posters, leaflets, articles in
scientific journals, educational materials for
schools, radio broadcasts, advertising spots
on TV and short texts on webpages.
Scientific conferences are also organized. In
2009, a questionnaire study revealed that
about 30% of the people who were
informed about the rational use of antibi-
otics stated that they adapted their antibiotic
use.14 The Antibiotic Awareness Day there-
fore seems a proven way to change pre-
scribing behavior. Finally, in Malta, a
nation-wide approach using educational and
motivational interventions led to more
responsible use of antibiotics. After this
awareness campaign a nation-wide reduc-
tion in the proportion of respondents who
stated that they had obtained antibiotics
without a doctor’s prescription came to the
fore.12
Governmental regulations on package
size: lower quality evidence 
In Spain, antibiotic consumption was
significantly decreased after adjusting the
package size of oral antibiotics.12 In
September 2011, an expert working group
was convened with the aim of reviewing the
size of the package for oral antibiotics. This
panel included a GP, a pediatrician, a phar-
macist, and government representatives. All
oral antibiotic packages were reviewed and
a proposal was made to adjust their size to
the most common dosage and duration of
treatment according to clinical practices.
From May 2012 to April 2014, there was a
transitory period of coexistence of the old
and adjusted packages. Over 900 packages
were adjusted. According to the ECDC
ESAC-Net surveillance data, this had a sig-
nificant impact on the antibiotic consump-
tion in terms of number of packages per
thousand inhabitants and per day.12
Vertical approaches at hospital ward
level
Prevention of surgical infections with S.
aureus: high-quality evidence
Reductions in use of antibiotics can also
be capitalized by a reduction of infections.
S. aureus is worldwide the most common
hospital-acquired infection.15 Infection rates
are increasing due to the widespread dis-
semination of methicillin-resistant S. aureus
(MRSA). Infection with MRSA is associat-
ed with substantial morbidity and
mortality.16 In 2008, there were an estimated
380,000 infections in EU hospitals. MRSA
accounts for 5400 attributable deaths and
for more than 1 million in-hospital days.
The attributable hospital costs caused by
MRSA are considerable, reaching approxi-
mately €380 million annually. Reducing the
number of S. aureus transmissions therefore
offers interesting opportunities. 
The control of S. aureus transmission
traditionally focused on preventing cross-
infection between patients. However, it has
been shown that most S. aureus infections
originate from patients’ own flora (i.e.,
presence in the nose).17 Approximately 20%
of the healthy population carries S. aureus
and is therefore considered a risk factor for
subsequent infection to various patient
groups. Removal of S. aureus from the nose
before surgery has shown to prevent infec-
tions. The Amphia Hospital Breda in the
                             Article
Figure 2. Costs and savings of the antimicrobial stewardship team.
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Netherlands developed a non-invasive
screen-and-treat strategy to eradicate nasal
S. aureus bacteria. The strategy entails rapid
identification of S. aureus carriers by means
of screening (a real-time polymerase-chain-
reaction assay), followed by treatment with
mupirocon nasal ointment and chlorhexi-
dine soap.
Jan Kluytmans and colleagues were the
first to study the effectiveness of the screen-
and-treat strategy in a double-blind, ran-
domized, controlled trial design.18 The
study in five Dutch hospitals proved statis-
tically and clinically significant reduction in
S. aureus infections during surgery. The rate
of S. aureus infection was 3.4% (17 of 504
patients) in the screen-and-treat strategy
group, compared to 7.7% (32 of 413
patients) in the placebo group. The results
of this trial provide solid evidence for this
preventive intervention: the risk of hospital
associated S. aureus infections was reduced
by nearly 60%. Moreover, a Cochrane
review conducted by researchers from the
same study group confirmed effective-
ness.19
The screen-and-treat strategy is also
highly cost-effective.20 The group per-
formed an economic evaluation in which all
hospital costs made during the 12 months
after (cardiothoracic or orthopedic) surgery
were taken into account. The mean total
costs for a screened-and-treated patient
undergoing surgery were considerably
lower than costs for a placebo-treated
patient (€8600 vs. €10,500, Figure 3). The
reduction in infections led to a shorter total
hospital stay (on average two days) and less
nursing time at the ICU. Given that screen-
ing is relatively cheap (around €20), and
treating even cheaper (€5 for the mupirocon
nasal ointment and €5 for the chlorhexidine
soap), the financial investments are almost
negligible. 
The results of this study show clear ben-
efit of the screen-and-treat strategy in car-
diothoracic and orthopedic surgery. A total
of €400,000 per thousand surgeries could be
saved, based on the nasal S. aureus carriage
rate of 20%. Worldwide millions of surgical
procedures are performed each year. Huge
numbers of patients would therefore benefit
from this screen-and-treat strategy, accom-
panied by large savings.
Diagnostic tests in primary care - high
quality evidence
A final example for reducing antibiotic
use is the reduction of unnecessary pre-
scriptions in primary care. Major drivers of
such unnecessary prescribing are diagnostic
uncertainty and patient expectations.21 An
intervention that has shown to address both
predictors effectively is the C-reactive pro-
tein (CRP) Point of Care Test, in combina-
tion with communication skills training.
The CRP Point of Care Test is a highly
accurate diagnostic tool to differentiate
between presumably viral and bacterial
infections, such as acute bronchitis and
pneumonia. A low outcome of the CRP test
result reassures the GP that other diagnos-
tics and antibiotic treatment are unneces-
sary. CRP tests can be done swiftly in
everyday general practice by using a finger
prick blood sample. Results are available in
a few minutes.
The effectiveness of this CRP Point of
Care Test in combination with enhanced
communication training was recently inves-
tigated in the Netherlands.22 The effective-
ness was studied in a large-scale, pragmatic,
randomized trial with a 1-month follow-up
period. The combined intervention resulted
in a statistically and clinically significant
reduction in the number of antibiotic pre-
scriptions (a prescription rate of 23% com-
pared to 68% in the control group).
Assuming nation-wide implementation in
the Netherlands, the researchers claimed
that between 150,000 and 240,000 antibiot-
ic prescriptions could be saved annually.
Importantly, patients’ recovery and satisfac-
tion were similar in both study groups,
despite the substantial reduction in antibiot-
ic prescribing.
The economic evaluation showed that
already one month after running the pro-
gram, cost-savings exceed the initial invest-
ments.23 Patients in the intervention group
required less additional diagnostics (e.g.,
chest X-ray and spirometry), used less
antibiotics, and visited the GP less often
than control group patients (accounting for
an average cost-saving of €22 per patient).
Given the low intervention costs (€15 per
patient) and the fact that the CRP test can be
performed in just three minutes, the feasi-
bility and financial investments cannot be
hurdles for further implementation.
Transferability and cost-effectiveness
of CRP Point of Care Test was studied in
four other EU countries (United Kingdom,
Poland, Spain, and Belgium).24 GPs across
nations were trained online to interpret CRP
tests adequately and to communicate these
effectively. The study proved transferability
between these countries: the antibiotic pre-
scribing rate in the intervention groups was
significantly lower (33%) than in the con-
trol groups (48%), despite differences
across European primary care settings.
Hence, the CRP Point of Care Test is an
example that interventions designed in one
country can be transferred to other countries
with different health systems and prescrib-
ing rates.
Discussion
The objective of the present paper was
to provide insight into the costs and poten-
tial health and financial gains associated
with infection control and policies to reduce
the spread of antimicrobial resistance. The
content of several European proven cost-
effective examples were described. Despite
some methodological limitations in some of
the studies, the evidence suggests that sev-
eral cost-effective approaches are available
to reduce the spread of antimicrobial resist-
ance efficiently. In addition, these examples
show that not only multifaceted and com-
plex approaches are cost-effective (e.g.,
antimicrobial stewardship teams), but also
smaller and more feasible approaches with
a high potential implementation can be
cost-effective (e.g., the CRP Point of Care
Test and the screen-and-treat strategy). EU-
wide implementation of (the most effective
components of) the proven cost-effective
examples described in this report may lead
to a reduction of infections with  microor-
ganisms, more adequate use of antimicro-
bials, and a reduction of antimicrobial
resistance rates. These outcomes will con-
tribute to improved patient safety and
patient health, leading to more sustainable
healthcare.
The cost-effectiveness of infection con-
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Figure 3. Mean hospital costs per patient for placebo and treatment group.
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trol and adequate use of antibiotics can be
further enhanced through regional coopera-
tion. Healthcare institutions are generally
seen as the source of antimicrobial resist-
ance. However, the high connectivity of
healthcare networks (e.g., the transfer of
patients between departments; or the trans-
fer of patients from curative to long-term
care, and vice versa) will impact the effec-
tiveness of infection control strategies and
adequate use of antibiotics. Healthcare
institutions should therefore cooperate
regionally and internationally to fight
antimicrobial resistance successfully.
Especially in areas with high levels of
cross-region and cross-border patient refer-
rals, since the weakest link in the healthcare
chain determines the effectiveness of pre-
vention. Intensive cooperation across
departments, institutions, nations, and sec-
tors is also in line with the One Health
Approach.25
In 2016, Jim O’Neill estimated that
over 40 billion USD is needed over the
coming decade to take global action on
antimicrobial resistance.26 Almost half of
this amount (16 billion USD) is needed to
promote the development of new antibiotics
to treat resistant patients in urgent need of
antibiotics. Although it is extremely impor-
tant to invest in extending the pipeline of
new antibiotics using market incentives
such as market entry rewards, we should not
neglect the importance of early prevention.
The examples in this report suggest that this
is possible in a cost-effective way and might
even generate substantial savings for
providers that spearhead these possibilities.
This paper has two important limita-
tions. First, the focus of the paper was to
give an overview of useful stewardship ini-
tiatives at different levels of healthcare. The
chosen method of citing only a few specifi-
cally selected proven cost-effective cases
contains an unavoidable selection bias in
itself.  Nevertheless, the cases show that
efficacious prevention at local, national and
international level can go hand in hand, not
only with cost-effective care, but (some-
times) also with substantial cost-savings.
This may help organizations in healthcare to
build a business case and invite them to start
a stewardship initiative. Second, the results
of some cases have not been published in
research reports or (peer-reviewed) research
articles. These results were retrieved from
lower quality evidence, such as oral confer-
ence presentations, personal communica-
tion with authors, and from (scientific)
magazines, which makes it hard to compare
the evidence.
Several key lessons can be learned from
the presented examples. These lessons may
help to design successful and cost-effective
policies to reduce the spread of antimicro-
bial resistance. First, the importance of
awareness about the relevance and benefits
of cost-effective policies. Second, the con-
tinuous surveillance and feedback in an
open dialogue culture. Third, sustained
implementation of cost-effective approach-
es across Europe.
Raising awareness about adequate
use of antibiotics
The first step for successful implemen-
tation and change is to raise awareness.27
Awareness of appropriate antibiotic use can
for example be effectively raised through
public health campaigns. A range of tools
can be used, including TV and radio spots,
information booklets/leaflets for patients
and healthcare institutions, press releases,
and awareness days. Studies in France,
Poland, and Malta have shown that public
health campaigns improve knowledge and
awareness about appropriate antibiotic use
dramatically. Moreover, these campaigns
have led to significant decreases in antibiot-
ic use. Although the cost-effectiveness of
public health campaigns has not been stud-
ied, the (self-reported) degrees of reduction
in antibiotic use suggests that these cam-
paigns are valuable strategies to effectively
raise awareness for a large audience.
Continuous surveillance and 
feedback on prescribing behavior
Dutch antimicrobial stewardship teams
decreased antimicrobial resistance in cura-
tive care with very good value for money.
Effective surveillance and feedback by
these teams have shown to lead to more
adequate prescribing of antibiotics, fewer
infections, shorter length of hospital stay,
and less antimicrobial resistance. Key in
this respect is the combination of closely
monitoring of healthcare professionals’
behavior (prescribing of antibiotics and
adherence to infection control guidelines)
and tailored (oral or written) feedback on
behavior. Preconditions are clear profes-
sional responsibilities in combination with
an open dialogue culture, based on open-
ness and trust.
Sustained implementation of cost-
effective approaches across Europe
A precondition for long-term effects of
these policies is a sustained implementation
(also by avoiding and overcoming of resist-
ance to change) of cost-effective approach-
es. Most examples in this report have
proven to be cost-effective in their study
setting; one example (CRP Point of Care
Test) has also proven to be transferable to
other EU countries. Our cost-effective data
are from Dutch studies, but the beneficiary
effects might be even higher in the majority
of European countries that encounter more
difficulties with antimicrobial prescriptions.
Conclusions
Given the rapid EU-wide spread of
antimicrobial resistance and the limited
pipeline of new antibiotics, cost-effective
interventions in the areas of public health
and care provision are urgently needed to
improve infection prevention and antimi-
crobial prescribing. We have presented the
cost-effectiveness of several antimicrobial
policies that have shown to improve antimi-
crobial prescribing and infection control
successfully and efficiently. Healthcare
institutions and professionals can benefit
from the presented studies by implementing
(the most effective elements of) antimicro-
bial policies. Policymakers can redesign
(parts of) their health system in such a way
that these policies are more sought for by
their agents. A sustained implementation
strategy holds the promise to improve
patient outcomes, while leading to substan-
tial cost-savings. This clearly adds to the
sustainability of EU-wide healthcare.
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